This stock is still cheap as it is in its infancy of...

This stock is still cheap as it is in its infancy of development. I came to know about it through a smallcap stock newsletter recommendation (before the china announcement) and have since added on my initial position post announcement. The china potential is vast for a wide variety of anti microbial product offering- a 1% of 3o million beijing chinese audience is 300k x nzd40 is about $12m and the potential is multiplied when it reaches 300m audience. The china market has a strong affinity with quality australian products - eg A2M, Blackmores, Capillano, and e commerce esp alibaba platform is definitely a great market entry strategy. Over the next 6 months, i see this going to a mcap of $100m. For me, i wouldnt be trading in and out of this stock.